title: Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas.
abstract: The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.
authors.affiliation: Dr. Adkins is an oncology pharmacist, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Walter Reed National Military Medical Center, Bethesda, Maryland. At the time this manuscript was written, he was an Oncology Pharmacy Resident (PGY-2) at Walter Reed National Military Medical Center. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army, Department of the Navy, or Department of Defense.
authors.forename: Kyle E
authors.initials: KE
authors.lastname: Adkins
authors.affiliation: Dr. Adkins is an oncology pharmacist, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Walter Reed National Military Medical Center, Bethesda, Maryland. At the time this manuscript was written, he was an Oncology Pharmacy Resident (PGY-2) at Walter Reed National Military Medical Center. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army, Department of the Navy, or Department of Defense.
authors.forename: Dominic A
authors.initials: DA
authors.lastname: Solimando
authors.affiliation: Dr. Adkins is an oncology pharmacist, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Walter Reed National Military Medical Center, Bethesda, Maryland. At the time this manuscript was written, he was an Oncology Pharmacy Resident (PGY-2) at Walter Reed National Military Medical Center. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army, Department of the Navy, or Department of Defense.
authors.forename: J Aubrey
authors.initials: JA
authors.lastname: Waddell